Roger Frechette, PhD – Entrepreneur-in-Residence, Advisor and Leadership Team, North Shore InnoVentures. Roger is also a co-founder and Partner in New England PharmAssociates, LLC, a life sciences executive and advisory services firm – and Sustaining Sponsor of NSIV. Previously, he was a co-founder of MaxThera, Inc., a drug discovery research company developing novel antibacterial agents to treat life-threatening infections. He served as VP of Chemistry and R&D Operations for MaxThera. The company was formed through the acquisition of the drug discovery portfolio developed at Genome Therapeutics Corporation, where Roger was a medicinal chemistry consultant. MaxThera’s antibacterial assets were sold in early 2010 to Biota Holdings Limited, a Melbourne Australia anti-infectives company. Prior to starting MaxThera, Roger was a independent drug discovery and life-sciences consultant following his role as Project Director at Paratek Pharmaceuticals, in Boston. At Paratek, he successfully led the team that discovered PTK0796 (currently in Phase III clinical trials), and directed the pre-clinical development program. Prior to Paratek, he was Associate Director of Chemistry at RiboGene, Inc, in Hayward, CA, where he built the chemistry department and managed two drug discovery programs in collaboration with a Japanese strategic partner (Dainippon Pharmaceuticals). He began his career as a medicinal chemist at the R.W. Johnson Pharmaceutical Research Institute (A Johnson and Johnson Company) in Raritan, NJ. He has a BA in chemistry from the College of the Holy Cross, a PhD in synthetic chemistry form Wesleyan University and was an NIH Post-Doctoral Fellow at Yale University.